A5033431709- melanin and skin pigmentation
- Biochemical Analysis and Sensing Techniques
- Olfactory and Sensory Function Studies
- Skin Protection and Aging
- Atherosclerosis and Cardiovascular Diseases
- Mast cells and histamine
- Delphi Technique in Research
- Dermatology and Skin Diseases
- Clinical practice guidelines implementation
- Health Systems, Economic Evaluations, Quality of Life
- Garlic and Onion Studies
- Horticultural and Viticultural Research
- Body Image and Dysmorphia Studies
- Angiogenesis and VEGF in Cancer
- Wound Healing and Treatments
- Veterinary Oncology Research
- Ocular Oncology and Treatments
- Allergic Rhinitis and Sensitization
- Nail Diseases and Treatments
- Autoimmune and Inflammatory Disorders
- Chemokine receptors and signaling
- Psoriasis: Treatment and Pathogenesis
- Drug-Induced Adverse Reactions
- Diagnosis and Treatment of Venous Diseases
- Inflammatory mediators and NSAID effects
New Cross Hospital
2022-2024
The Royal Wolverhampton NHS Trust
2022-2024
Walsall Healthcare NHS Trust
2023-2024
John Wiley & Sons (United States)
2023
Liechtenstein Institute
2023
Oxfam
2023
Hudson Institute
2023
John Wiley & Sons (United Kingdom)
2023
Walsall Manor Hospital
2022-2023
University of Birmingham
2022-2023
The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint emerged. This guideline for the segmental nonsegmental been developed by members Vitiligo Task Force other colleagues. It summarizes evidence-based expert-based recommendations (S1 level).
The treatment of vitiligo can be challenging. Up-to-date agreed consensus recommendations on the use topical and systemic therapies to facilitate clinical management are currently lacking.To develop internationally agreed-upon expert-based for vitiligo.In this statement, a consortium 42 international experts four patient representatives participated in different online live meetings strategy vitiligo. At least two summarized evidence topics included algorithms. A survey was then given core...
The treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, extent, goals. Vitiligo usually requires a long-term approach. To improve management worldwide, clear up-to-date guide based international consensus with uniform stepwise recommendations is needed.To reach an nomenclature to develop algorithm for diagnosis, assessment, vitiligo.In this statement, consortium 42 experts four patient representatives participated in online live...
Abstract Linked Comment: K. Ezzedine and A.G. Pandya. Br J Dermatol 2022; 186:3–4. Plain language summary available online
Pigment Cell & Melanoma ResearchVolume 28, Issue 3 p. 363-369 Meeting Report Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus Viktoria Eleftheriadou, Corresponding Author Eleftheriadou Centre of Evidence Based Dermatology, University Nottingham, UKCORRESPONDENCE Khaled Ezzedine and e-mails: khaled.ezzedine@chu-bordeaux.fr; viktoria.eleftheriadou@nottingham.ac.ukSearch more papers by this authorKim Thomas, Kim Thomas UKSearch authorNanja van Geel,...
Vitiligo is the most frequent depigmentation disorder of skin and cosmetically psychologically devastating. A recently updated Cochrane systematic review 'Interventions for vitiligo' showed that research evidence treatment vitiligo poor, making it difficult to make firm recommendations clinical practice.
Although genetic studies have found an inverse relationship between vitiligo and skin cancer, epidemiological evidence is conflicting. We investigated the risk of cancer in adults with using United Kingdom electronic primary care records from Optimum Patient Care Research Database 2010-2020. Vitiligo cases were age, sex, general practitioner practice matched to population controls without vitiligo. Incidence melanoma, nonmelanoma cancers (squamous cell carcinoma basal carcinoma), actinic...
UK studies examining vitiligo burden and vitiligo-related healthcare resource utilization (HCRU) are lacking.
The Vitiligo Global Issues Consensus Conference (VGICC), through an international e-Delphi consensus, concluded that 'repigmentation' and 'maintenance of gained repigmentation' are essential core outcome measures in future vitiligo trials. This VGICC position paper addresses these topics two sections includes atlas depicting repigmentation patterns color match. first section delineates mechanisms characteristics repigmentation, the second summarizes outcomes meeting discussions e-surveys on...
A major obstacle of evidence‐based clinical decision making is the use nonstandardized, partly untested outcome measurement instruments. Core Outcome Sets (COSs) are currently developed in different medical fields to standardize and improve selection outcomes instruments trials, order pool results trials or allow indirect comparison between interventions. COS an agreed minimum set that should be measured reported all a specific disease trial population. The international, multidisciplinary...
There is no cure or firm clinical recommendations for the treatment of vitiligo. One main issues heterogeneity outcome measures used in randomized controlled trials To define successful repigmentation from patients' point view and to propose how when should be evaluated We conducted three workshops with patients vitiligo their parents caregivers. Workshop 1 was held at World Vitiligo Day (Detroit, MI), workshop 2 University Texas Southwestern Medical Center 3 Pigmentation Institute Southern...
Summary Results of clinical trials are the most important information source for generating external evidence. The use different outcomes across trials, which investigate similar interventions patient groups, significantly limits interpretation, comparability and application trial results. Core outcome sets (COSs) aim to overcome this limitation. A COS is an agreed standardized collection that should be measured reported in all a specific condition. Outcome Set Initiative within Cochrane...
Evidence for the effectiveness of vitiligo treatments is limited. To determine (i) handheld narrowband UVB (NB‐UVB) and (ii) a combination potent topical corticosteroid (TCS) NB‐UVB, compared with TCS alone, localized vitiligo. A pragmatic, three‐arm, placebo‐controlled randomized controlled trial (9‐month treatment, 12‐month follow‐up). Adults children, recruited from secondary care community, aged ≥ 5 years active affecting < 10% skin, were 1 : to receive (mometasone furoate 0·1% ointment...
Hand-held NB-UVB units are lightweight devices that may overcome the need to treat vitiligo in hospital-based phototherapy cabinets, allowing early treatment at home enhance likelihood of successful repigmentation. The pilot Hi-Light trial examined feasibility conducting a large multi-centre randomised controlled (RCT) on use such by exploring recruitment, adherence, acceptability, and patient education. This was feasibility, double-blind, multi-centre, parallel group placebo-controlled...
Background Systematic reviews suggest that narrowband ultraviolet B light combined with treatments such as topical corticosteroids may be more effective than monotherapy for vitiligo. Objective To explore the clinical effectiveness and cost-effectiveness of corticosteroid compared (1) hand-held (2) light/topical combination treatment localised Design Pragmatic, three-arm, randomised controlled trial 9 months a 12-month follow-up. Setting Sixteen UK hospitals – participants were recruited...